menu
    • menu
    [{"orgOrder":0,"company":"Vicebio","sponsor":"Medicxi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXB-211","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vicebio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicebio \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Vicebio \/ Medicxi"},{"orgOrder":0,"company":"Vicebio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VXB-241","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Vicebio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vicebio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vicebio \/ Undisclosed"},{"orgOrder":0,"company":"Vicebio","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Series B Financing","leadProduct":"VXB-241","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vicebio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Vicebio \/ TCGX","highestDevelopmentStatusID":"6","companyTruncated":"Vicebio \/ TCGX"},{"orgOrder":0,"company":"Vicebio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Acquisition","leadProduct":"VXB-241","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vicebio","amount2":1.6000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.6000000000000001,"dosageForm":"Injection","sponsorNew":"Vicebio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Vicebio \/ Sanofi"},{"orgOrder":0,"company":"Vicebio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VXB-251","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vicebio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vicebio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vicebio \/ Undisclosed"},{"orgOrder":0,"company":"Vicebio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Acquisition","leadProduct":"VXB-241","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vicebio","amount2":1.6000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.6000000000000001,"dosageForm":"Injection","sponsorNew":"Vicebio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Vicebio \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Vicebio

    Menu

    Vicebio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXB-251,VXB-241,VXB-213,VXB-221,VXB-232

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults

                            Details : VXB-251 is a vaccine drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Respiratory Tract Diseases.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 19, 2025

                            Lead Product(s) : VXB-251,VXB-241,VXB-213,VXB-221,VXB-232

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXB-241,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : $1,600.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi Completes Acquisition of VICEBIO

                            Details : Through the acquisition of VXB-241, a vaccine targeting respiratory syncytial virus (RSV), the deal aims to advance RSV research and development.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $1,150.0 million

                            December 04, 2025

                            Lead Product(s) : VXB-241,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : $1,600.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXB-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : $1,600.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi Acquires Vicebio, Expanding Respiratory Vaccines Pipeline

                            Details : Through the acquisition of VXB-241, a vaccine targeting an undisclosed pathogen, the deal aims to advance infectious disease prevention.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $1,150.0 million

                            July 22, 2025

                            Lead Product(s) : VXB-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : $1,600.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXB-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : TCGX

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Vicebio Secures $100M For RSV/hMPV Vaccine Phase 1 Clinical Study

                            Details : The financing aims to support the clinical development of VXB-241, which is being evaluated in the early-stage clinical studies for the targeting both RSV and hMPV viruses.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 23, 2024

                            Lead Product(s) : VXB-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : TCGX

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXB-241

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

                            Details : VXB-241 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 15, 2024

                            Lead Product(s) : VXB-241

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vicebio

                            United Kingdom arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXB-211

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Medicxi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicebio Launched by Medicxi to Advance the Molecular Clamp Technology and Develop Next Generation RSV Vaccine

                            Details : RSV vaccine candidate (VXB-211), best-in-class efficacy as a ready-to-use fully liquid formulation,for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 21, 2022

                            Lead Product(s) : VXB-211

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Medicxi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.